When was scPharmaceuticals founded?

scPharmaceuticals was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is scPharmaceuticals located?

scPharmaceuticals is headquartered in Lexington, United States. It is registered at Burlington, Massachusetts.

How many employees does scPharmaceuticals have?

As of Jul 31, 2026, the latest employee count at scPharmaceuticals is 40.

Is scPharmaceuticals a funded company?

scPharmaceuticals is a funded company, having raised a total of $78.7M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 26, 2014.

When was the latest funding round of scPharmaceuticals?

scPharmaceuticals' latest funding was a $***** Series B round on Jan 06, 2017, with participation from 4 investors. Its primary sector is Drug Delivery. In United States, the Drug Delivery sector has seen $245M in funding in 2026 to date.

Where does scPharmaceuticals rank among its competitors?

scPharmaceuticals ranks 1st amongst 79 active competitors, of which 29 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was CeQur, which secured $100M in Jun, 2026.

Who are the top competitors of scPharmaceuticals?

scPharmaceuticals' top competitors include CeQur, Vaxxas and Hero Patch. Among them, CeQur secured the most recent funding round in June, 2026.

scPharmaceuticals - 2026 Company Profile, Funding & Competitors

scPharmaceuticals is an acquired company based in Lexington (United States), founded in 2013. It operates as a Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure. scPharmaceuticals has raised $78.7M in funding from Orbimed and Sun Pharma. The company has 79 active competitors, including 29 funded and 13 that have exited. Its top competitors include companies like CeQur, Vaxxas and Hero Patch.

Company Details

Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure. The company has developed a device called sc2Wear Pump that facilitates subcutaneous drug administration over durations, rates, and volumes that can be tailored to specific drugs. The pipeline includes Furosemide for heart failure, Ceftriaxone, and Ertapenem to treat bacterial infections.

Website: scpharmaceuticals.com
Social
Registered Address: Burlington, Massachusetts

Key Metrics

Founded Year

2013

Location

Lexington, United States

Stage

Acquired

Total Funding

$78.7M in 4 rounds

Latest Funding Round

Series B, Jan 06, 2017, $*****

Investors

Orbimed & 5 more

Ranked

1^st among 79 active competitors

Employee Count

40 as on Jul 31, 2026

Similar Companies

CeQur & 100 more

Exit Details

Acquired by MannKind Corp (Aug 25, 2025)

View scPharmaceuticals' full profile

scPharmaceuticals is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
SCPHARMACEUTICALS INC. CIN: 1604950 , United States, Active	Feb 18, 2013	$10M - $50M (As on Dec 31, 2024)	-	-
SCPHARMACEUTICALS, INC. CIN: 465184075 , United States, Active	Dec 26, 999	-	158 (As on Dec 31, 2024)	-
Scpharmaceuticals Inc. CIN: 20241620248 , United States, Active	Jun 06, 2024	-	-	-

scPharmaceuticals got acquired by MannKind Corp on Aug 25, 2025 at an acquisition amount of $*****.

Click here to take a look at scPharmaceuticals's acquisition in detail

scPharmaceuticals has raised a total funding of $78.7M over 4 rounds. Its first funding round was on Mar 26, 2014. Its latest funding round was a Series B round on Jan 06, 2017 for $*****. 4 investors participated in its latest round. scPharmaceuticals has 6 institutional investors.

Here is the list of recent funding rounds of scPharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 06, 2017	7786039	Series B	3017303	1339148	8608585	2172861
Sep 06, 2016	6084842	Series A	9550140	7208820	5519731	2180006
Feb 04, 2016	1961255	Series A	1622907	9796123	9404951	8834793

Access funding benchmarks and valuations. Sign up today!

View details of scPharmaceuticals's funding rounds and investors

scPharmaceuticals' employee count trend

scPharmaceuticals has 40 employees as of Jul 26. Here is scPharmaceuticals's employee count trend over the years:

Employee count trend for scPharmaceuticals

Uncover scPharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of scPharmaceuticals include CeQur, Vaxxas and Hero Patch. Here is the list of Top 10 competitors of scPharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	scPharmaceuticals 2013, Lexington (United States), Acquired	Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure	$78.7M	Gilde Healthcare, Lundbeck Foundation & 4 others	59/100
2nd	CeQur 2008, Horw (Switzerland), Series E	Developer of wearable insulin delivery patch	$492M	Endeavour Vision, Schroders & 7 others	59/100
3rd	Vaxxas 2010, Brisbane (Australia), Series D	Developer of a needle-free patch technology for vaccine delivery applications	$91.2M	One Ventures, UniQuest & 12 others	59/100
4th	Hero Patch 2019, Boston (United States), Series A	Developer of antibodies or small molecules for drug delivery	$20.5M	Big Pi Ventures, Velocity Partners & 5 others	55/100
5th	Starton 2017, New York City (United States), Seed	Developer of drug delivery solution and drugs for treating oncology	$9.29M	LOVE Pharma, Goldfingr	52/100
6th	Scilex Holding 2019, Palo Alto (United States), Public	Developer of non-opioid therapies for acute and chronic pain	-	Frazier Life Sciences	52/100
7th	Corsair Phama 2014, San Francisco (United States), Series B	Developer of drugs for the treatemnt of cardiac diseases	$23M	New Rhein, Primavera & 3 others	52/100
8th	AFYX Therapeutics 2013, Copenhagen (Denmark), Series A	Developer of drug patches for the treatment of mucosal diseases	$33.3M	Sofinnova Investments, Nordic Venture & 6 others	47/100
9th	Valeritas 2003, Bridgewater (United States), Acquired	Developer of wearable insulin patch pumps for insulin delivery through the skin	$231M	Welsh, Carson, Anderson & Stowe, Abingworth ... & 12 others	46/100
10th	Samyang BioPharm 2011, Seoul (South Korea), Funding Raised	Portfolio of drug loaded transdermal patches and wound closure medical devices	-	KIC Europe, MassBio	45/100